A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-15
Publisher
Informa UK Limited
Online
2021-04-29
DOI
10.1080/14740338.2021.1924147
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting
- (2021) S. Ribero et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicenter cohort study
- (2020) A.V. Marzano et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa
- (2020) Vassiliki Tzanetakou et al. Expert Opinion On Drug Safety
- A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain
- (2020) Alice Gottlieb et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study
- (2020) John W. Frew et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment
- (2020) Paolo Gisondi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
- (2020) Rebecca Haberman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy
- (2020) Zachary E. Holcomb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long‐term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open‐label phase 3 results
- (2020) Akimichi Morita et al. JOURNAL OF DERMATOLOGY
- Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis
- (2019) Leah Ellis Wells et al. PEDIATRIC DERMATOLOGY
- Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa
- (2019) L. Prussick et al. BRITISH JOURNAL OF DERMATOLOGY
- Determining the Optimal Dose of Infliximab for Treatment of Hidradenitis Suppurativa
- (2019) Ashley N. Oskardmay et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
- (2019) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective
- (2019) Youwei Bi et al. AAPS Journal
- Biologics exposure during pregnancy and breastfeeding in a psoriasis patient
- (2019) Cristina Mugheddu et al. Dermatologic Therapy
- Long‐term therapy with anakinra in hidradenitis suppurativa in three patients
- (2019) Raphaël André et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
- (2019) Akimichi Morita et al. JOURNAL OF DERMATOLOGY
- Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
- (2019) Gerd R. Burmester et al. ADVANCES IN THERAPY
- High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa
- (2019) Mondana H. Ghias et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effect of biologic drugs on renal function in psoriasis patients with chronic kidney disease
- (2019) Jalal Maghfour et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
- (2019) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study
- (2018) H Chiu et al. ACTA DERMATO-VENEREOLOGICA
- Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
- (2018) R. B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab
- (2018) Sze-Wen Ting et al. CLINICAL DRUG INVESTIGATION
- Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection
- (2018) Francesca Peccerillo et al. Dermatologic Therapy
- Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development
- (2018) Rebecca Matro et al. GASTROENTEROLOGY
- MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study
- (2018) Theodora Kanni et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
- (2018) Christos C. Zouboulis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Five successful pregnancies with antenatal anakinra exposure
- (2018) Chelsey J F Smith et al. RHEUMATOLOGY
- Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist
- (2018) Katharina Köstner et al. RHEUMATOLOGY
- Ustekinumab Exposure during Conception and Pregnancy in Patients with Chronic Plaque Psoriasis - a case series of 10 pregnancies
- (2018) N. Watson et al. BRITISH JOURNAL OF DERMATOLOGY
- Hormonal, Stem Cell and Notch Signaling as Possible Mechanisms of Disease in Hidradenitis Suppurativa: a Systems-Level Transcriptomic Analysis
- (2018) T. D. Gauntner BRITISH JOURNAL OF DERMATOLOGY
- Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C
- (2018) S.A.R. Siegel et al. BRITISH JOURNAL OF DERMATOLOGY
- Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
- (2018) Toshiyuki Watanabe et al. International Journal of Rheumatic Diseases
- Guselkumab in the Treatment of Hidradenitis Suppurativa: A Retrospective Chart Review
- (2018) Rachel G. Casseres et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Guselkumab in the treatment of severe Hidradenitis suppurativa
- (2018) M Kovacs et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn’s Disease Treated Until 33 Weeks of Gestation
- (2017) Catherine R Rowan et al. Journal of Crohns & Colitis
- Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
- (2017) Igor Snast et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature
- (2017) S. Piaserico et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety of secukinumab in hepatitis B virus
- (2017) S.L. Bevans et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors
- (2017) Taryn Youngstein et al. RHEUMATOLOGY
- Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
- (2017) Zheng Zhang et al. BMJ Open
- Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
- (2016) J.L. Blok et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety of secukinumab in the treatment of psoriasis
- (2016) Andrew Blauvelt Expert Opinion On Drug Safety
- Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
- (2016) Mette Julsgaard et al. GASTROENTEROLOGY
- Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS
- (2016) Stephanie M. Gallitano et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab in Patients with Active Noninfectious Uveitis
- (2016) Glenn J. Jaffe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
- (2016) Alexa B. Kimball et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa
- (2016) Vassiliki Tzanetakou et al. JAMA Dermatology
- Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study
- (2015) Corinna Weber-Schoendorfer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Hepatotoxicity Associated with the Use of Anti-TNF-α Agents
- (2015) Joshua B. French et al. DRUG SAFETY
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study
- (2015) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
- (2014) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy
- (2014) Nabeel Khan et al. Expert Opinion On Drug Safety
- The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
- (2014) Daniel A. Gold et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection
- (2014) H. Saeki et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis
- (2014) A. Alsenaid et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
- (2014) David S Hong et al. LANCET ONCOLOGY
- TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment
- (2014) Mihaela C. Micu et al. RHEUMATOLOGY
- Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease
- (2013) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- (2013) Alexa B. Kimball et al. ANNALS OF INTERNAL MEDICINE
- The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
- (2013) H.-Y. Chiu et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa
- (2013) G.R. Vinding et al. BRITISH JOURNAL OF DERMATOLOGY
- An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
- (2013) Kieron S. Leslie et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
- (2012) R. Navarro et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Incidence of Hidradenitis Suppurativa and Associated Factors: A Population-Based Study of Olmsted County, Minnesota
- (2012) Benjamin G. Vazquez et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
- (2012) Irene Cosmatos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Degree of TNF-α/IL-10 Cytokine Elevation Correlates With IVF Success Rates in Women Undergoing Treatment With Adalimumab (Humira) and IVIG
- (2011) Edward E. Winger et al. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
- (2011) I. Miller et al. BRITISH JOURNAL OF DERMATOLOGY
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
- (2011) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
- Ustekinumab for the treatment of HIV psoriasis
- (2011) Vasileios Paparizos et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy
- (2011) Roberto Pérez-Alvarez et al. MEDICINE
- A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa
- (2010) Masahiro Amano et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy
- (2010) Monika Arenbergerova et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Blocking interleukin-1β in acute and chronic autoinflammatory diseases
- (2010) C. A. Dinarello JOURNAL OF INTERNAL MEDICINE
- Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
- (2010) Annika Grant et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- -Secretase Gene Mutations in Familial Acne Inversa
- (2010) B. Wang et al. SCIENCE
- Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?
- (2009) L Matusiak et al. ACTA DERMATO-VENEREOLOGICA
- Long-term Successful Adalimumab Therapy in Severe Hidradenitis Suppurativa
- (2009) Ricardo Blanco et al. ARCHIVES OF DERMATOLOGY
- ORIGINAL ARTICLE: Treatment with Adalimumab (Humira®) and Intravenous Immunoglobulin Improves Pregnancy Rates in Women Undergoing IVF*
- (2008) Edward E. Winger et al. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies
- (2008) Jean E. Revuz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now